SOHO 2026 | New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses emerging therapeutic approaches for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Prof. Ribera highlights that newer bispecific agents may further improve efficacy, tolerability, and ease of administration, with the potential of making long-term survival achievable for most adults with Ph+ ALL. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, the problem of the intensification therapy is on the table, clearly. So, in the modern therapy just with ponatinib and blinatumomab, we can reduce the chemotherapy to the minimal expression. But you can have a step ahead, including the new bispecific agents, such as subcutaneous blinatumomab, surovatamig, MK compound also. And really, we think that we can provide even more efficacy and especially better tolerability and feasibility of administration...
Well, the problem of the intensification therapy is on the table, clearly. So, in the modern therapy just with ponatinib and blinatumomab, we can reduce the chemotherapy to the minimal expression. But you can have a step ahead, including the new bispecific agents, such as subcutaneous blinatumomab, surovatamig, MK compound also. And really, we think that we can provide even more efficacy and especially better tolerability and feasibility of administration. So I think that with these new compounds it’s conceivable now to have long-term survival for 80 to 90 percent of adults with Ph-positive ALL. So this is a great achievement of course.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
